Last reviewed · How we verify
CPP-ACFP
This drug is a small molecule that targets the [insert target here, if known].
This drug is a small molecule that targets the [insert target here, if known]. Used for Phase 3 clinical trials are ongoing for CPP-ACFP, but specific indications are not publicly available..
At a glance
| Generic name | CPP-ACFP |
|---|---|
| Also known as | MI varnishTM (GC Corporation, Tokyo, Japan), RecaldentTM (CPP-ACP) |
| Sponsor | Plovdiv Medical University |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, I do not have enough information to provide a deeper explanation of the mechanism.
Approved indications
- Phase 3 clinical trials are ongoing for CPP-ACFP, but specific indications are not publicly available.
Common side effects
- Unknown
Key clinical trials
- Efficacy of Different Agents in Treatment of Initial Caries on Smooth Surfaces in Permanent Teeth in Children (PHASE3)
- Clinical Evaluation of Dental Fluororsis Treatment Modalities (NA)
- Clinical Evaluation of Different Minimal Invasive Treatment Modalities of Mild to Moderate Dental Fluorosis Using A Visual Analog Scale (NA)
- Effect of Self-Assembling Peptides on the Progression of Non-Cavitated Proximal Caries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPP-ACFP CI brief — competitive landscape report
- CPP-ACFP updates RSS · CI watch RSS
- Plovdiv Medical University portfolio CI